Engineered a Gemcitabine Nano‐Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics
Small · 2025
DOI: 10.1002/smll.202410629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Qida Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China. Hauptthemen laut MEDLINE: Deoxycytidine, Pancreatic Neoplasms, Prodrugs, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Zhejiang Provincial Natural Science Foundation.
Abstract (Originalsprache)
The desmoplastic nature characterized by dense tissue and poor vascular conditions in pancreatic cancer (PDAC) poses a significant barrier to effective chemotherapy. Targeting the extracellular matrix and reducing desmoplasia in the tumor microenvironment is a rational approach to improve the penetration and efficacy of gemcitabine (GEM) in PDAC. Herein, a small molecular self‐assembly nano‐prodrug is developed for the “three‐in‐one” co‐delivery of GEM chemotherapeutics, all‐trans retinoic acid (ATRA), and nitric oxide (NO) donors, decorated with PDAC‐homing targeting peptide. Stimulated by the PDAC microenvironment, the nano‐prodrug releases ATRA that quiesces activated pancreatic stellate cells to alleviate stromal desmoplasia. Simultaneously, it generates abundant NO to induce a vasodilatory effect as well as a “nanomotor” effect. This combinational nano‐prodrug delivery strategy, with a dual enhancement of drug penetration dynamics, effectively improves the distribution and bioavailability of the co‐delivered GEM into the deep and dense pancreatic tumor tissue, which leads to significant amplification of tumor growth inhibition in different PDAC mouse models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, China.
- Department of Chemical and Biomolecular Engineering, National University of Singapore, 4 Engineering Drive, Singapore, 117585, Singapore.
- Healthcare Management Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
- Zhejiang Provincial Key Laboratory of Pancreatic Disease, Hangzhou, 310003, China.
- Innovation Center for the Study of Pancreatic Diseases, Hangzhou, 310003, China.
ORCID-Profile: Bowen Li
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Zhejiang Provincial Natural Science Foundation
- Key Program of Medical Scientific Research Foundation of Zhejiang Province
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Hu, Q., Zhang, F., Li, B., Jin, P., Huang, J., Yao, Z., Zhao, X., Shao, S., Wang, M., Ping, Y., & Liang, T. (2025). Engineered a Gemcitabine Nano‐Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics. Small. https://doi.org/10.1002/smll.202410629
Vancouver
Hu Q, Zhang F, Li B, Jin P, Huang J, Yao Z, et al. Engineered a Gemcitabine Nano‐Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics. Small. 2025. doi:10.1002/smll.202410629
BibTeX
@article{Hu2025,
author = {Hu, Qida and Zhang, Fu and Li, Bowen and Jin, Piaopiao and Huang, Junming and Yao, Zhuo and Zhao, Xinyu and Shao, Shiyi and Wang, Meng and Ping, Yuan and Liang, Tingbo},
title = {Engineered a Gemcitabine Nano‐Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202410629}
}
EUVIMED